Parkinson disease treated with a suspected dopamine receptor agonist.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001590:Benztropine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004298:Dopamine; D005069:Evaluation Studies as Topic; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011339:Probenecid; D011743:Pyrimidines / Q000627:therapeutic use; D011950:Receptors, Cholinergic / Q000187:drug effects*; D014202:Tremor / Q000188:drug therapy; D014282:Trihexyphenidyl / Q000627:therapeutic use
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D010879:Piperazines; D010919:Placebos; D011743:Pyrimidines; D011950:Receptors, Cholinergic; D001590:Benztropine; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl; D000547:Amantadine; D011339:Probenecid; D004298:Dopamine; D006719:Homovanillic Acid